

TruScreen Share Placement

TRUSCREEN LIMITED (TRU)

TruScreen Limited advises that it has issued new shares as follows:

Class of Security:	Ordinary Shares (TRU)
Number issued:	7,142,856 ordinary shares at NZD 21 cents each fully paid
Payment:	Cash on subscription
Percentage of total Class of Securities issued:	3.4% (of the total number of ordinary shares on issue post completion of the issue)
Reason for the issue:	<ul style="list-style-type: none">• Expand commercial growth in China, Africa, India and Latin America;• Fund clinical and familiarisation trials as required for product improvement and acceptance in government programs;• Expand manufacturing facilities and supply capabilities;• Build-up inventory; and• Continued product refinement.
Authority of issue	Director's Resolution and NZAX Listing Rule 7.3.5
Terms of issue:	The new shares are credited as fully paid, and rank in all respects equally with the shares already on issue
Total number of securities of the Class in existence after the issue:	209,345,477
Date of issue:	6 September, 2018

TRUSCREEN LIMITED

Martin Dillon

Chief Executive Officer

-ENDS-

For more information visit www.truscreen.com or contact Martin Dillon, TruScreen Chief Executive Officer, eMail: martindillon@truscreen.com

About TruScreen:

TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.

